Neurokine Pharmaceuticals Inc.
OTC Bulletin Board : NEUKF

Neurokine Pharmaceuticals Inc.

September 08, 2010 14:49 ET

Neurokine Announces Formation of Scientific and Clinical Advisory Board

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 8, 2010) - Neurokine Pharmaceuticals Inc. (OTCBB:NEUKF) is pleased to announce that Dr. Patrick McGeer has joined its newly formed Scientific and Clinical Advisory Board.

Dr. McGeer is universally acknowledged as one of the leading researchers on Alzheimer's and other neurodegenerative diseases and is among the world's top 100 most highly cited neuroscientists. In addition to research, Dr. Patrick McGeer also served as MLA and B.C. Cabinet Minister until 1986, and created the Open Learning Institute of B.C. In 2004, Dr. McGeer was awarded the Henry Wisniewski prize given to the top Alzheimer's disease researcher. He has received an Honourary Doctor of Science degree from UBC, the Medal of Service from the Cam Coady Foundation, the Clarke Institute of Psychiatry Prize from the University of Toronto, and a lifetime achievement award from the Science Council of B.C. Dr. McGeer was appointed as Officer of the Order of Canada in 1995, and Fellow of the Royal Society of Canada in 2002.

About Neurokine

Neurokine Pharmaceuticals Inc. focuses on development of new use for existing marketed products for diseases mediated by acute and chronic inflammatory reactions. The company is developing proprietary encapsulation technology to allow better blood brain barrier penetration to initiate or enhance therapeutic effects of anti-inflammatory drugs in the treatment of neurodegenerative diseases.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Neurokine or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of Neurokine's products, the competitive environment within the industry, the ability of Neurokine to continue to expand its operations, the level of costs incurred in connection with Neurokine's expansion efforts, economic conditions in the industry and the financial strength of Neurokine's customers and suppliers. Neurokine does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information

  • Neurokine Pharmaceuticals Inc.
    Ahmad Doroudian, Ph.D.
    President and CEO
    (604) 805-7783
    www.neurokine.com